News and Press Releases
Research | CFTR Modulators FDA Approves Expansion of Modulators for People With Certain Rare Mutations

The U.S. Food and Drug Administration (FDA) today expanded its approval of three CFTR modulators to include additional people with CF who have certain rare mutations. The approval enables more than 600 individuals with CF who were not previously eligible for modulators to access drugs that treat the underlying cause of their disease for the first time.

| 3 min read
About the CF Foundation | Get Involved CF Foundation busca la participación de las comunidades afroamericana, latina, indígena, asiática, de Medio Oriente y otras personas de color

Poner atención a la diversidad de voces es fundamental a medida que continuamos con  nuestra meta de escuchar, aprender y actuar contra el racismo y la discriminación.

| 4 min read
About the CF Foundation | Get Involved CF Foundation Seeks Input from Communities of Color

Hearing from diverse voices is critical as we continue our journey to listen, learn, and take action against racism and discrimination.

| 3 min read
CFTR Modulators | About the CF Foundation A Message From Our CEO

The CF Foundation has successfully completed a sale of its remaining stake in royalties related to Vertex's CFTR modulators for an upfront payment of $575 million and a potential future payment of $75 million, bringing additional resources to the fight against CF.

| 3 min read
Research | CFTR Modulators Roche Acquires Potential CF Therapies; Plans to Develop Alternatives to CFTR Modulators

Roche has acquired a set of potentiator compounds from Enterprise Therapeutics and intends to study them for the treatment of CF. The Cystic Fibrosis Foundation previously provided funding to Enterprise to develop these potential medicines.

| 3 min read
Clinical Trials Anti-Inflammatory Drug for CF Fails to Meet Goal of Late-Stage Clinical Trial

Corbus Pharmaceuticals reported today that the Phase 2b clinical trial of its potential anti-inflammatory drug lenabasum did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.

| 2 min read
CFTR Modulators | About the CF Foundation | Clinician Resources CF Foundation Leaders Provide Expertise During ICER Public Meeting

On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.

| 3 min read
Drug Pipeline FDA Approves Kalydeco for Infants as Young as 4 Months

The U.S. Food and Drug Administration has approved the use of Kalydeco® (ivacaftor) for infants with cystic fibrosis as young as four months who have certain mutations.

| 3 min read
Drug Pipeline | Clinical Trials Vertex Announces Positive Study Results for Trikafta in Children Ages 6-11

Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.

| 2 min read
Drug Pipeline Vertex Asks FDA to Expand CFTR Modulators to Additional Mutations

Vertex Pharmaceuticals Inc. has submitted three supplemental New Drug Applications to the U.S. Food and Drug Administration (FDA) to expand eligibility for Trikafta® (elexacaftor/tezacaftor/ivacaftor), Symdeko® (tezacaftor/ivacaftor and ivacaftor) and Kalydeco® (ivacaftor) to additional rare CFTR mutations.

| 2 min read